1.The status of research on estimated glomerular filtration rate and its challenges
Chinese Journal of Laboratory Medicine 2014;(6):404-407
Chronic kidney disease ( CKD ) is a worldwide public health problem.Glomerular filtration rate ( GFR ) is a key indicator for early diagnosis and accurate classification of CKD , how to estimate GFR accurately and conveniently has been a difficulty and hot-points.We describes the development of several major eGFR equations based on creatinine and cystatin C , analysis the impact of the different research methods on performance of equation , and discusses the issue in research and application of eGFR in China.Accordingly make the following recommendations ( 1 ) Expand the study size ( multiple centers) and participants number , then develop and validate eGFR equations based on Chinese population ;(2) Standardize the gold standardof GFR in the study and unify the analysis and evaluation methods;(3) Promote the consistency and standardization of creatinine and cystatin C which is the basis for the wide range of applications of the eGFR formula.
2.Brief Analysis on the Spillover Effects of Multinational Pharmaceutical Enterprises'Research&Devel-opment Institutions in China
China Pharmacy 2001;0(09):-
OBJECTIVE:To bring the spillover effects of multinational pharmaceutical enterprises'Research&Develop-ment institutions intofull play in China.METHODS:The routes for the exertion of spillover effects and the main restrictive factors of multinational pharmaceutical enterprises were analyzed and some strategies to enhance the spillover effects were put forward.RESULTS&CONCLUSION:The absorbing ability of the domestic pharmaceutical enterprises should be enhanced in China;the flow of the personnel between the multinational enterprises and the domestic pharmaceutical enterprises should be accelerated.We should participate actively in the Research&Development system of multinational pharmaceutical enterprises,reinforce the protection of intellectual property and promote the Research&Development investment of multinational phar-maceutical enterprises in China.
3.Discussion on Pharmaceutical Enterprises'Outsourcing Strategy Based on Value Chain
China Pharmacy 2005;0(15):-
OBJECTIVE:To discuss the outsourcing strategy of pharmaceutical enterprises.METHODS:The feasibility and the necessity of carrying out outsourcing strategy in pharmaceutical enterprises were analyzed based on value chain theory;and the current outsourcing strategies carried out in China pharmaceutical enterprises were evaluated.RESULTS&CON?CLUSION:Outsourcing is a feasible choice for our pharmaceutical enterprises,by which their competitive edge can be im?proved effectively.
4.Epstein-Barr virus and lymphoma
Yajuan QIU ; Mingzhi ZHANG ; Ling LI
Journal of International Oncology 2011;38(5):387-389
More and more studies have found that EBV infection is closely related to the occurrence, development, treatment and prognosis of lymphoma. The treatment of EBV-positive lymphoma bases mainly on combined chemo-radiotherapy together with ganciclovir, acyclovir and other antiviral drugs. Also there are novel ways to treat EBV positive- lymphoma including CD70 monoclonal antibody, butyrate, etc. The only way to prevent EBV infection is to inoculate anti-viral vaccine. The criterion of treating EBV positive-lymphoma remains to be further investigated.
5.62 case reports of using Daclizumab after renal transplantation
Wei LIU ; Feng QIU ; Jianyu LING
Chinese Journal of Organ Transplantation 2003;0(06):-
Objective To investigate the efficacy and safety of anti CD25 Ab (Zenapax;Daclizumab) induction therapy in 62 patients following renal transplantation. Methods Sixty-two renal transplant recipients treated with Daclizumab induction therapy were analyzed retrospectively from Sep. 1999 to May 2004. Main immunosuppressive therapy regimen consisted of steroids cyclosporine and mycophenolate mofetil in all recipients after operation. According to Daclizumab dosage, these recipients were divided into 1-dose group, 2-dose group and over 2-dose group. All patients received Daclizumab 1 h before operation.Results The patients subject to Daclizumab were followed up from 3 months to 57 months. Seven of them had acute rejection ( 11.3 %) at intervals for 10.3 months, from 2 months to 14 months. Patient who had acute rejection at 10th month after operation lost his graft at 13th month after transplantation for graft dysfunction. The incidence of acute rejection was 15.6 % among 45 patients followed up over 12 months. Conclusions Induction therapy of Daclizumab could decrease the incidence of acure rejection, delay the time of acute rejection and relieve the severity of rejection. More graft can be long-survival. We can lower the dosage of CsA effectively and safely after induction of Daclizumab.
6.Effect of calcium intakes on calcium-regulating hormones and bone mineral density during pregnancy and postpartum periods
Ling QIU ; Yixiang SU ; Yuping PENG
Chinese Journal of Endocrinology and Metabolism 1986;0(03):-
Thirty-six healthy women were divided into 3 groups according to their calcium intake at week 18 of gestation. The levels of their blood calcium, phosphate, parathyroid hormone (PTH) and calcitonin were assayed during pregnancy and postpartum, and bone mineral density ( BMD) was measured postpartum. The levels of PHI and calcitonin were increasing with advancing pregnancy and reached the highest at the end of pregnancy. The women with higher calcium intake during pregnancy period had higher BMD than that of the women with ordinary diet during pregnancy period.
7.The relationship of angiotension-Ⅱ to portal hypertension in patients with liver cirrhosis
Ling LIU ; Li ZHOU ; Bingsheng QIU
Chinese Journal of Immunology 1999;0(12):-
Objective:To study the relationships of portal hypertensions to vasoactive substances-angiotensin(AT-Ⅱ)in cirrhosis patients.Methods:48 patients with liver cirrhosis(LC)(including 18 patients with compensated LC and 30 patients with decompensated LC) and 32 normal controls(NC) were studied. Color duplex doppler ultrasonography was used to study portal venous and splenic venous blood flow(PVBF and SVBF).Also,the blood concentration of AT-Ⅱ was detected.Then,analyze the correlation between PVBF and SVBF to AT-Ⅱ.Results:Portal hyperdynamic exists in cirrhosis patients from beginning to the end. Low level of AT-Ⅱ in compensated LC patient has no relation with portal hyperdynamic, high level of AT-Ⅱ in decompensated LC has positive relation with portal hyperdynamic.Conclusion:This study has directed significance of clinical treatment and diagnosis.
8.Effects of OGP derivate H86A on Bone Metrology in Ovariectomized Rats
Jing ZHANG ; Ling CHEN ; Mingcai QIU
Chinese Journal of Prevention and Control of Chronic Diseases 2006;0(02):-
Objective To investigate the effects of OGP (10-14) and its derivate H86A on bone metrology in rats with ovariecto-my-reduced osteoporosis. Methods Thirty-two female Sprague-Dawley rats, three months old, were randomly divided into 4 groups. Rats in groups 1 to 3 were bilaterally ovariectomized(OVX) and the others in group 4 were sham-operated. After the operation, rats in group 1 and group 2 were received derivate of OGP(10-14) H86A daily at different concentration. Group 3 were given placebo. Rats were killed after 12 weeks. Left tibias were disconnected and made into non-decalcified bone slice, and then they were detected and analyzed on indexes which were relative with bone metrology. Results Compared with Group 3, no other indexes except OV/BV was obviously different in rats with high dose H86A (P
10.Determination of droxidopa in human plasma and pharmacokinetic features
Ling ZHONG ; Yanchuan QIU ; Jingchuan SHANG
Journal of Third Military Medical University 2003;0(11):-
Objective To propose a method for the determination of droxidopa concentration in human plasma by HPLC method for the study of the pharmacokinetics of droxidopa.Methods After a single oral dose of 200 mg droxidopa capsule was administered to 12 healthy Chinese male volunteers,we used perchloric acid to precipitate proteinum and then determined the droxidopa concentration in plasma by HPLC.The pharmacokinetic parameters of droxidopa were calculated by 3P87 software.Results The linear range was 0.025-2 ?g/ml.Pharmacokinetic parameters were: T1/2(108.50?30.78)min,AUC(185.74?26.41) ?g?ml-1?min-1,CL(1.08?0.08)ml/min,Tmax(99.90?10.05)min,Cmax(0.74?0.08)?g/ml.At 10 h after administration,droxidopa was eliminated from the blood almost completely.Conclusion The method we proposed is sensitive,reproducible,and easy to operate.Pharmacokinetics of droxidopa in vivo is fitted to two-compartment model.